Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine in Patients With Inflammatory Bowel Disease on Vedolizumab or Anti-Tumor Necrosis Factor Therapy
RZV demonstrated robust immunogenicity and favorable safety profile in patients with IBD receiving either vedolizumab or anti-TNF therapy. Both cellular and humoral immune responses persisted through 425 days postvaccination.
Authors
- Mary S. Hayney (ORCID: https://orcid.org/0000-0003-3307-5634)
- Francis A. Farraye (ORCID: https://orcid.org/0000-0001-6371-2441)
- Abdul-Rahman Abusalim
- Freddy Caldera (ORCID: https://orcid.org/0000-0003-1960-6611)
- Harshitha Mogallapalli
Institutions
- University of Wisconsin–Madison (US)
- UW Health University Hospital (US)
- Jacksonville College (US)
- WinnMed (US)
- Mayo Clinic in Florida (US)
- Wisconsin Division of Public Health (US)
Publication Details
- Journal
- Clinical and Translational Gastroenterology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.14309/ctg.0000000000000924
- Citations
- 1
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.35